For two years, Ovid spun a Phase II miss as a win. The drug just failed Phase III

5 years ago
R&D

Corey Good­man in­tro­duces Tal­lac Ther­a­peu­tics with a $62M Se­ries A, hop­ing to fight sol­id tu­mors through in­nate and ...

5 years ago
Financing

With eyes on an IPF fran­chise, Gala­pa­gos push­es sec­ond can­di­date in­to a dose-find­ing study

5 years ago
R&D

Af­ter Mod­er­na and Pfiz­er's stel­lar re­sults, the come­back play­ers at No­vavax face big ques­tions about their ...

5 years ago
R&D
Coronavirus

News brief­ing: Mer­ck’s Roger Perl­mut­ter buys his first sol­id tu­mor TriN­KET from Drag­on­fly; Vi­Gen­eron to ex­pand ...

5 years ago
News Briefing

Bridge­Bio grabs a sec­ond pri­or­i­ty re­view for the port­fo­lio — giv­ing Per­cep­tive start­up cause to cel­e­brate

5 years ago
FDA+

As­traZeneca of­floads for­mer crown jew­el Crestor as it con­tin­ues to re­fo­cus on on­col­o­gy drugs

5 years ago
Deals

The FDA spells out 4 rea­sons why it hates Min­er­va’s NDA ideas — but the biotech is go­ing for it any­way

5 years ago
FDA+

A top can­cer R&D ex­ec at Genen­tech joins the ex­o­dus, jump­ing to a mar­quee Chi­na biotech as the new on­col­o­gy chief, ...

5 years ago
People

Covid-19 roundup: Pfiz­er and Mod­er­na take their vac­cines to the EMA; Chief of Staff Mark Mead­ows calls Hahn to White ...

5 years ago
Coronavirus

Agios re­turns pos­i­tive PhI­II da­ta in a rare blood dis­or­der as it seeks to move past re­cent can­cer set­backs

5 years ago
R&D

Roche shelved these psy­chi­a­try drugs. So its for­mer head of neu­ro cooked up some new plans — and raised $59M for ...

5 years ago
Financing
Startups

Not so fast, Mr Pres­i­dent: Trump's plan for low­er­ing pre­scrip­tion drug prices hits a road­block, as Cana­da bans bulk ...

5 years ago
People
Pharma

Re­gen­eron teams with gene ther­a­py pi­o­neer James Wil­son, adapt­ing its Covid-19 an­ti­body cock­tail to an AAV-based nasal ...

5 years ago
Deals
Coronavirus

News brief­ing: Four biotechs an­nounce IPO terms, set­ting the pace to round out a busy year; FDA sets PDU­FA date for ...

5 years ago
News Briefing

FDA of­fers ‘break­through’ sta­tus for a HER2xHER2 bis­pe­cif­ic at the top of Zymeworks’ pipeline

5 years ago
R&D

Zio­pharm and a mi­nor­i­ty in­vestor spent Thanks­giv­ing fight­ing over con­trol of the com­pa­ny as ac­tivist at­tack con­tin­ues ...

5 years ago
Pharma

Covid-19 roundup: No­vavax de­lays US, Mex­i­co vac­cine tri­al (again); In­dia in­ves­ti­gates re­port­ed side ef­fects in ...

5 years ago
Coronavirus

Shop­ping for a hol­i­day pipeline gift? How about an an­ti-NGF an­ti­body from Astel­las?

5 years ago
Pharma

Cap­ping Pas­cal So­ri­ot’s big turn­around, the an­a­lysts at Cowen say As­traZeneca is poised for a stel­lar year

5 years ago
Bioregnum
R&D

Sev­er­al weeks af­ter get­ting hit with an RTF, Y-mAbs lands ap­proval for its oth­er neu­rob­las­toma can­di­date

5 years ago
FDA+

FDA gives Rhythm the green light for set­melan­otide, a drug aimed at re­duc­ing obe­si­ty in cer­tain ge­net­ic dis­or­ders

5 years ago
FDA+

As­traZeneca CEO So­ri­ot plans new study to test that con­tro­ver­sial 90% ef­fi­ca­cy fig­ure, wait­ing for US da­ta be­fore ...

5 years ago
Coronavirus

Ki­naset launch­es with $40M and a JAK in­hibitor from Vec­tura's old pipeline

5 years ago
Financing
Startups
First page Previous page 772773774775776777778 Next page Last page
A service from the Financial Times